Literature DB >> 20155426

Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma.

Mingzhen Ying1, Dawei Li, Linjun Yang, Mei Wang, Ning Wang, Ying Chen, Miaoxia He, Yajie Wang.   

Abstract

PURPOSE: Constitutive activation of JAK/STAT pathway is observed in various solid tumors and hematological malignancies. SOCS3 acts as a key negative regulator of JAK/STAT pathway and represents one of the candidate tumor suppressor genes. In the current study, we aimed to evaluate SOCS3 expression in breast carcinoma and to explore the prognostic significance of SOCS3.
METHODS: The expression of SOCS3 was measured by Western blot and immunohistochemistry in breast carcinoma cells and a large cohort of tissue microarray, respectively.
RESULTS: Among 367 human primary breast tumors, SOCS3 protein was detected in 103 patients. Deficient SOCS3 expression correlated significantly with lymph node metastasis (P = 0.003), blood vessel invasion (P = 0.029), VEGF (P = 0.001) and Ki-67 (P = 0.027). Univariate and multivariate analyses revealed that SOCS3 expression was an independent prognostic factor for disease-free survival (P < 0.0001). A positive SOCS3 protein expression correlated significantly with a low pSTAT3 protein expression in breast carcinoma (P = 0.015). The patients with a SOCS3 (+)/pSTAT3 (-) phenotype had a better prognosis than any other combination (DFI: P < 0.0001, BCSS: P = 0.013).
CONCLUSIONS: Deficient expression of SOCS3 is associated with an aggressive phenotype and portends a poor clinical outcome in breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20155426     DOI: 10.1007/s00432-010-0819-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  33 in total

1.  SOCS-1 participates in negative regulation of LPS responses.

Authors:  Reiko Nakagawa; Tetsuji Naka; Hiroko Tsutsui; Minoru Fujimoto; Akihiro Kimura; Tatsuo Abe; Ekihiro Seki; Shintaro Sato; Osamu Takeuchi; Kiyoshi Takeda; Shizuo Akira; Koichi Yamanishi; Ichirou Kawase; Kenji Nakanishi; Tadamitsu Kishimoto
Journal:  Immunity       Date:  2002-11       Impact factor: 31.745

2.  Positive and negative roles of IL-6, STAT3, and SOCS3 in inflammatory arthritis.

Authors:  Ichiko Kinjyo; Masanobu Ohishi; Takanori Shouda; Takashi Kobayashi; Akihiko Yoshimura
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

3.  SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases.

Authors:  Joanne Elliott; Yvonne Suessmuth; Linda M Scott; Krystyna Nahlik; Mary Frances McMullin; Stefan N Constantinescu; Anthony R Green; James A Johnston
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

4.  Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma.

Authors:  Ravitharan Krishnadasan; Carlo Bifulco; Julie Kim; Sofya Rodov; Arthur W Zieske; Gary J Vanasse
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

5.  Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis.

Authors:  Hisanobu Ogata; Takashi Kobayashi; Takatoshi Chinen; Hiromi Takaki; Takahito Sanada; Yasumasa Minoda; Keiko Koga; Giichi Takaesu; Yoshihiko Maehara; Mitsuo Iida; Akihiko Yoshimura
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

6.  Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3.

Authors:  A W Roberts; L Robb; S Rakar; L Hartley; L Cluse; N A Nicola; D Metcalf; D J Hilton; W S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

7.  Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.

Authors:  R Garcia; T L Bowman; G Niu; H Yu; S Minton; C A Muro-Cacho; C E Cox; R Falcone; R Fairclough; S Parsons; A Laudano; A Gazit; A Levitzki; A Kraker; R Jove
Journal:  Oncogene       Date:  2001-05-03       Impact factor: 9.867

8.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.

Authors:  Guilian Niu; Kenneth L Wright; Mei Huang; Lanxi Song; Eric Haura; James Turkson; Shumin Zhang; Tianhong Wang; Dominic Sinibaldi; Domenico Coppola; Richard Heller; Lee M Ellis; James Karras; Jacqueline Bromberg; Drew Pardoll; Richard Jove; Hua Yu
Journal:  Oncogene       Date:  2002-03-27       Impact factor: 9.867

9.  SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation.

Authors:  Yutaka Takahashi; Nick Carpino; James C Cross; Miguel Torres; Evan Parganas; James N Ihle
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

10.  SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Yao-Tsung Yeh; Shen-Nien Wang; Sz-Chi Hung; Wan-Tzu Chen; Chu-Ho Huang; Chee-Yin Chai
Journal:  Pathology       Date:  2008-10       Impact factor: 5.306

View more
  16 in total

Review 1.  SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use?

Authors:  R Mahony; S Ahmed; C Diskin; N J Stevenson
Journal:  Cell Mol Life Sci       Date:  2016-05-02       Impact factor: 9.261

2.  Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma.

Authors:  Wen-Yong Wu; Jun Li; Zheng-Sheng Wu; Chang-LE Zhang; Xiang-Ling Meng; Peter E Lobie
Journal:  Exp Ther Med       Date:  2011-04-11       Impact factor: 2.447

Review 3.  gp130 at the nexus of inflammation, autoimmunity, and cancer.

Authors:  J S Silver; C A Hunter
Journal:  J Leukoc Biol       Date:  2010-07-07       Impact factor: 4.962

4.  Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer.

Authors:  Jingyu Deng; Xuguang Jiao; Honggen Liu; Liangliang Wu; Rupeng Zhang; Baogui Wang; Yi Pan; Xishan Hao; Han Liang
Journal:  Tumour Biol       Date:  2013-07-04

5.  Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.

Authors:  Yiwei Gao; Velasco Cimica; Nancy C Reich
Journal:  J Biol Chem       Date:  2012-04-30       Impact factor: 5.157

6.  Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures.

Authors:  Hongyu Kong; Qiongwen Zhang; Yunhui Zeng; Hong Wang; Mengqian Wu; Tianying Zheng; Yanzhang Zeng; Huashan Shi
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  Prognostic value of ZFP36 and SOCS3 expressions in human prostate cancer.

Authors:  J-G Zhu; D-B Yuan; W-H Chen; Z-D Han; Y-X Liang; G Chen; X Fu; Y-K Liang; G-X Chen; Z-L Sun; Z-Z Liu; J-H Chen; F-N Jiang; W-D Zhong
Journal:  Clin Transl Oncol       Date:  2015-11-13       Impact factor: 3.405

8.  SOCS3 is an endogenous inhibitor of pathologic angiogenesis.

Authors:  Andreas Stahl; Jean-Sebastian Joyal; Jing Chen; Przemyslaw Sapieha; Aimee M Juan; Colman J Hatton; Dorothy T Pei; Christian G Hurst; Molly R Seaward; Nathan M Krah; Roberta J Dennison; Emily R Greene; Elisa Boscolo; Dipak Panigrahy; Lois E H Smith
Journal:  Blood       Date:  2012-07-12       Impact factor: 22.113

9.  Loss of expression and function of SOCS3 is an early event in HNSCC: altered subcellular localization as a possible mechanism involved in proliferation, migration and invasion.

Authors:  Carlos Rossa; Gunhild Sommer; Luis C Spolidorio; Steven A Rosenzweig; Dennis K Watson; Keith L Kirkwood
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

10.  A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Authors:  Kristine L Stump; Lily D Lu; Pawel Dobrzanski; Cynthia Serdikoff; Diane E Gingrich; Ben J Dugan; Thelma S Angeles; Mark S Albom; Mark A Ator; Bruce D Dorsey; Bruce A Ruggeri; Matthew M Seavey
Journal:  Arthritis Res Ther       Date:  2011-04-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.